Brought to you by 
Savara brings in initial $3.2mm in Series B round; adds $7.4mm
21 Mar 2013
Executive Summary
Pulmonary drug delivery firm Savara Pharmaceuticals has raised $3.2mm so far through its Series B venture round. (An extension to the financing is expected in the near future.) The Keiretsu Forum was joined by current shareholders, for a total of 117 investors. In addition to the new money, Savara raised $3.5mm via a recent bridge financing that converted to Series B shares and $1.9mm from an Emerging Technology Fund equity conversion. Proceeds will be put towards the advancement of AeroVanc through Phase IIa as the first inhaled antibiotic for Staphylococcus aureus in cystic fibrosis patients.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Savara brings in initial $3.2mm in Series B round; adds $7.4mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice